Chengdu Kanghong Pharmaceutical Group 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Xiao Ke

최고 경영자

CN¥2.0m

총 보상

CEO 급여 비율	n/a
CEO 임기	14.4yrs
CEO 소유권	8.7%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	6.5yrs

최근 관리 업데이트

Recent updates

CEO

Xiao Ke (41 yo)

14.4yrs

테뉴어

CN¥2,045,500

보상

Mr. Xiao Ke serves as a General Manager and President of Chengdu Kanghong Pharmaceuticals Group Co., Ltd., and Director since June 21, 2010 and served as Vice President.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Xiao Ke	GM, President & Director	14.4yrs	CN¥2.05m	8.73% CN¥ 1.6b
Jin Qun Yin	VP & Director	8.2yrs	CN¥5.85m	0.038% CN¥ 7.2m
Jian Rong Zhong	VP & Director	16.4yrs	CN¥1.43m	1.15% CN¥ 216.7m
Lin Wang	Non-Independent Director	13.4yrs	데이터 없음	데이터 없음
Demin Zhou	Independent Director	1.3yrs	CN¥50.00k	데이터 없음
Zhirong Zhang	Non-Independent Director	1.3yrs	데이터 없음	데이터 없음
Jian Qun Yang	Employee Representative Supervisor	4.9yrs	데이터 없음	0.0016% CN¥ 307.0k
Zun Hong Ke	Chairman of the Board	23.8yrs	CN¥1.32m	22.58% CN¥ 4.3b
Wen Xian Gong	Chairman of the Supervisory Board	13.4yrs	데이터 없음	3.55% CN¥ 668.2m
Yin Ying Yang	Employee Supervisor	4.9yrs	데이터 없음	데이터 없음
Hongguang Deng	Independent Director	1.3yrs	CN¥50.00k	데이터 없음
Nan Xu	Independent Director	1.3yrs	CN¥50.00k	데이터 없음

6.5yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 이사회: 002773 의 이사회는 경험(평균 재직 기간 6.5 년)으로 간주됩니다.

Chengdu Kanghong Pharmaceutical Group 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Chengdu Kanghong Pharmaceutical Group Co., Ltd, Annual General Meeting, May 16, 2024

Insufficient new directors

High number of new directors

Chengdu Kanghong Pharmaceutical Group Co., Ltd, Annual General Meeting, May 20, 2022

High number of new directors

High number of new directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.31 (vs CN¥0.33 in 3Q 2023)

Chengdu Kanghong Pharmaceutical Group Co., Ltd to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 16%

Second quarter 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.27 in 2Q 2023)

Chengdu Kanghong Pharmaceutical Group Co., Ltd to Report First Half, 2024 Results on Aug 23, 2024

Dividend increased to CN¥0.38

Investor sentiment improves as stock rises 19%

Chengdu Kanghong Pharmaceutical Group Co., Ltd Proposes Final Cash Dividend for the Year 2023

Chengdu Kanghong Pharmaceutical Group Co., Ltd, Annual General Meeting, May 16, 2024

First quarter 2024 earnings released: EPS: CN¥0.41 (vs CN¥0.30 in 1Q 2023)

Chengdu Kanghong Pharmaceutical Group Co., Ltd to Report Q1, 2024 Results on Apr 25, 2024

Investor sentiment improves as stock rises 19%

Chengdu Kanghong Pharmaceutical Group Co., Ltd to Report Fiscal Year 2023 Results on Apr 25, 2024

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings released: EPS: CN¥0.33 (vs CN¥0.24 in 3Q 2022)

Chengdu Kanghong Pharmaceutical Group Co., Ltd to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.26 in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

Chengdu Kanghong Pharmaceutical Group Co., Ltd Announces Final Cash Dividend on Share A for 2022, Payable on June 6, 2023

Investor sentiment improves as stock rises 15%

Insufficient new directors

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.25 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.26 (vs CN¥0.21 in 2Q 2021)

Chengdu Kanghong Pharmaceutical Group Co., Ltd Announces Cash Dividend for A Shares for the Year 2021, Payment date is 08 June 2022

Chengdu Kanghong Pharmaceutical Group Co. Ltd. Approves Cash Dividend for the Year 2021

Chengdu Kanghong Pharmaceutical Group Co., Ltd Proposes Final Cash Dividend for the Year 2021

Chengdu Kanghong Pharmaceutical Group Co., Ltd, Annual General Meeting, May 20, 2022

First quarter 2022 earnings released: EPS: CN¥0.32 (vs CN¥0.25 in 1Q 2021)

High number of new directors

Third quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.28 in 3Q 2020)

High number of new directors

Second quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.18 in 2Q 2020)

Chengdu Kanghong Pharmaceuticals Group Co., Proposes Final Cash Dividend for the Year 2020

First quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.20 in 1Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

New 90-day low: CN¥35.28

Full year 2020 earnings released: EPS CN¥0.96 (vs CN¥0.82 in FY 2019)

Revenue misses expectations

Chengdu Kanghong Pharmaceutical Group Receives Special Protocol Assessments from the Food and Drug Administration for Three New Indications for Its Biologic Drug Conbercept

New 90-day low: CN¥35.44

New 90-day low: CN¥39.81

Investor sentiment improved over the past week

New 90-day high: CN¥47.89

Chengdu Kanghong Pharmaceuticals Group Co., Ltd Announces Completion 36-Week Primary Endpoint Visits of Phase Iii Trial of Conbercept

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

Chengdu Kanghong Pharmaceuticals Group Co., Ltd to Report Q3, 2020 Results on Oct 27, 2020

New 90-day low: CN¥42.93

New 90-day high - CN¥51.18

Earnings released

Chengdu Kanghong Pharmaceuticals Group Co., Ltd to Report First Half, 2020 Results on Aug 26, 2020

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령